-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly Says 52-Week Data from TOGETHER-PsO and TOGETHER-PsA Phase 3b trials of the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) Vs. Taltz Alone Shows Improved and Durable Efficacy in Patients With Psoriatic Disease and Obesity

Benzinga·08/31/2026 11:06:17
Listen to the news
  • At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed in the TOGETHER-PsO and TOGETHER-PsA trials
  • Systemic inflammation and metabolic outcomes continued to improve or were sustained at one year with Taltz and Zepbound compared to Taltz alone in pre-specified, exploratory endpoints
  • Data from first-of-their-kind studies contribute to the understanding of immunometabolic health